RU2509764C2 - 1н-хиназолин-2,4-дионы - Google Patents
1н-хиназолин-2,4-дионы Download PDFInfo
- Publication number
- RU2509764C2 RU2509764C2 RU2011131276/04A RU2011131276A RU2509764C2 RU 2509764 C2 RU2509764 C2 RU 2509764C2 RU 2011131276/04 A RU2011131276/04 A RU 2011131276/04A RU 2011131276 A RU2011131276 A RU 2011131276A RU 2509764 C2 RU2509764 C2 RU 2509764C2
- Authority
- RU
- Russia
- Prior art keywords
- quinazolin
- dioxo
- dihydro
- trifluoromethyl
- ampa receptor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C07D239/96—Two oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C207/00—Compounds containing nitroso groups bound to a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/56—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in ortho-position
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/64—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by singly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
- C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C229/66—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring the carbon skeleton being further substituted by doubly-bound oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/18—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups bound to carbon atoms of carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C265/00—Derivatives of isocyanic acid
- C07C265/12—Derivatives of isocyanic acid having isocyanate groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
- C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
- C07D249/06—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
- C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
- C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D309/10—Oxygen atoms
- C07D309/12—Oxygen atoms only hydrogen atoms and one oxygen atom directly attached to ring carbon atoms, e.g. tetrahydropyranyl ethers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Furan Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Dental Preparations (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
Изобретение относится к N-[2,4-диоксо-6-(тетрагидрофуран-2-ил)-7-трифторметил-1,4-дигидро-2H-хиназолин-3-ил]метансульфонамиду и N-[6-(1-изопропоксиэтил)-2,4-диоксо-7-трифторметил-1,4-дигидро-2H-хиназолин-3-ил]метансульфонамиду, которые обладают антагонистической активностью в отношении рецептора АМРА. Изобретение также относится к фармацевтической композиции и к применениям указанных соединений для получения лекарственных средств, предназначенных для лечения состояния, опосредованного АМРА, и, прежде всего, для лечения эпилепсии или шизофрении. 5 н. и 1 з.п. ф-лы, 81 пр.
Description
Claims (6)
1. N-[2,4-Диоксо-6-(тетрагидрофуран-2-ил)-7-трифторметил-1,4-дигидро-2H-хиназолин-3-ил]метансульфонамид.
2. N-[6-(1-Изопропоксиэтил)-2,4-диоксо-7-трифторметил-1,4-дигидро-2H-хиназолин-3-ил]метансульфонамид.
3. Соединения по любому из пп.1 и 2 для применения в качестве лекарственного средства, обладающего антагонистической активностью в отношении рецептора АМРА.
4. Фармацевтическая композиция, ингибирующая рецептор АМРА, содержащая соединение по любому из пп.1 и 2.
5. Применение соединения по любому из пп.1 и 2 для получения лекарственного средства, предназначенного для лечения состояния, опосредованного рецептором АМРА.
6. Применение соединения по любому из пп.1 и 2 для получения лекарственного средства, предназначенного для лечения эпилепсии или шизофрении.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0507298.8 | 2005-04-11 | ||
GBGB0507298.8A GB0507298D0 (en) | 2005-04-11 | 2005-04-11 | Organic compounds |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007141566/04A Division RU2435760C2 (ru) | 2005-04-11 | 2006-04-10 | 1н-хиназолин-2,4-дионы |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2011131276A RU2011131276A (ru) | 2013-02-10 |
RU2509764C2 true RU2509764C2 (ru) | 2014-03-20 |
Family
ID=34610935
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007141566/04A RU2435760C2 (ru) | 2005-04-11 | 2006-04-10 | 1н-хиназолин-2,4-дионы |
RU2011131276/04A RU2509764C2 (ru) | 2005-04-11 | 2006-04-10 | 1н-хиназолин-2,4-дионы |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2007141566/04A RU2435760C2 (ru) | 2005-04-11 | 2006-04-10 | 1н-хиназолин-2,4-дионы |
Country Status (36)
Country | Link |
---|---|
US (4) | US7655666B2 (ru) |
EP (4) | EP2476671A1 (ru) |
JP (2) | JP4898783B2 (ru) |
KR (2) | KR101162827B1 (ru) |
CN (2) | CN102807531A (ru) |
AR (1) | AR053047A1 (ru) |
AU (2) | AU2006233639B2 (ru) |
BR (1) | BRPI0608617A2 (ru) |
CA (1) | CA2601986C (ru) |
CY (2) | CY1113573T1 (ru) |
DK (2) | DK2468732T3 (ru) |
EC (1) | ECSP12007795A (ru) |
ES (2) | ES2524316T3 (ru) |
GB (1) | GB0507298D0 (ru) |
GT (2) | GT200600144AA (ru) |
HK (1) | HK1113790A1 (ru) |
HR (2) | HRP20120867T1 (ru) |
IL (2) | IL185544A (ru) |
IN (1) | IN2012DN00785A (ru) |
JO (1) | JO2770B1 (ru) |
MA (1) | MA29411B1 (ru) |
MX (1) | MX2007012592A (ru) |
MY (2) | MY149070A (ru) |
NO (1) | NO20075749L (ru) |
NZ (2) | NZ590463A (ru) |
PE (2) | PE20061306A1 (ru) |
PL (2) | PL1871749T3 (ru) |
PT (2) | PT2468732E (ru) |
RU (2) | RU2435760C2 (ru) |
SA (2) | SA06270089B1 (ru) |
SG (1) | SG177182A1 (ru) |
SI (2) | SI2468732T1 (ru) |
TN (1) | TNSN07383A1 (ru) |
TW (2) | TWI385158B (ru) |
WO (1) | WO2006108591A1 (ru) |
ZA (2) | ZA200807421B (ru) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
GB0507298D0 (en) * | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
TW200934497A (en) * | 2007-11-13 | 2009-08-16 | Organon Nv | Heterocyclic derivatives |
WO2010046399A1 (en) * | 2008-10-22 | 2010-04-29 | Novartis Ag | Combinations for the treatment of migraine |
IN2012DN00235A (ru) * | 2009-07-23 | 2015-05-01 | Novartis Ag | |
EP2308866A1 (de) | 2009-10-09 | 2011-04-13 | Bayer CropScience AG | Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide |
WO2011048150A1 (en) | 2009-10-20 | 2011-04-28 | Novartis Ag | Use of 1h-quinazoline-2,4-diones |
BR112012018358A2 (pt) | 2009-12-21 | 2016-08-09 | Bayer Cropscience Ag | tienilpiri(mi)dinilazol e seu uso para controlar fungos fitopatogênicos |
MX2012007320A (es) * | 2009-12-22 | 2012-07-20 | Novartis Ag | Formulacion que comprende antagonistas ampa de 1h-quinazolina-2, 4-diona, en la forma de tabletas de liberacion inmediata y su preparacion. |
CN102906085A (zh) * | 2010-05-20 | 2013-01-30 | 诺瓦提斯公司 | 2,4-二氧代-1,4-二氢-2h-喹唑啉-3-基-磺酰胺衍生物 |
BR112012033290A2 (pt) * | 2010-06-24 | 2016-11-22 | Novartis Ag | uso de 1h-quinazolina-2,4-dionas |
CN103080102B (zh) | 2010-07-09 | 2016-08-24 | 拜耳知识产权有限责任公司 | 作为杀虫剂的邻氨基苯甲酰胺衍生物 |
US9067881B2 (en) | 2011-01-24 | 2015-06-30 | Novartis Ag | 4-tolyl-ethynyl-octahydro-indole-1-ester derivatives |
MX2014002693A (es) | 2011-09-07 | 2014-06-04 | Novartis Ag | Uso de 1h-quinazolina-2,4-dionas para usarse en la prevencion o el tratamiento de epilepsia fotosensible. |
WO2014042176A1 (ja) * | 2012-09-14 | 2014-03-20 | キッセイ薬品工業株式会社 | 縮合複素環誘導体の製造方法およびその製造中間体 |
AU2014369982B2 (en) | 2013-12-24 | 2019-04-18 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
WO2016023826A1 (en) * | 2014-08-11 | 2016-02-18 | Hydra Biosciences, Inc. | Quinazoline-2,4(1h,3h)-dione derivatives as trcp5 modulators for the treatment of neuropsychiatry disorders |
MX2020011980A (es) | 2018-05-10 | 2021-03-26 | Zoetis Services Llc | Depsipéptidos endoparasiticidas. |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019346A1 (en) * | 1994-01-14 | 1995-07-20 | Sandoz Ltd. | Quinazoline-2,4-diones |
US6562839B1 (en) * | 1999-02-26 | 2003-05-13 | Kyorin Pharmaceutical Co., Ltd. | 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both |
RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
Family Cites Families (63)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US535475A (en) | 1895-03-12 | Governor | ||
GB281309A (en) | 1926-11-27 | 1928-03-29 | Inventia Patent Verwert Ges | Improvements in or relating to brushing machines having replaceable brush members |
US2957880A (en) | 1953-12-23 | 1960-10-25 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
US2838519A (en) | 1953-12-23 | 1958-06-10 | Ciba Pharm Prod Inc | Process for the conversion of stereoisomers |
US3310553A (en) | 1962-09-25 | 1967-03-21 | Pfizer & Co C | Alkylated thioxathenesulfonamides |
US3539573A (en) | 1967-03-22 | 1970-11-10 | Jean Schmutz | 11-basic substituted dibenzodiazepines and dibenzothiazepines |
BE759371A (fr) | 1969-11-24 | 1971-05-24 | Bristol Myers Co | Azaspirodecanediones heterocycliques et procedes pour leur preparation |
US3637661A (en) | 1970-03-04 | 1972-01-25 | Ciba Geigy Corp | 10-hydroxy-10 11-dihydro-dibenzazepine derivative |
GB1422263A (en) | 1973-01-30 | 1976-01-21 | Ferrosan As | 4-phenyl-piperidine compounds |
US4536518A (en) | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
FI834666A (fi) | 1982-12-23 | 1984-06-24 | Ciba Geigy Ag | Foerfarande foer framstaellning av nya aralkyltriazolfoereningar. |
WO1988001270A1 (en) * | 1986-08-21 | 1988-02-25 | Pfizer Inc. | Pyridopyrimidinediones |
KR880007433A (ko) | 1986-12-22 | 1988-08-27 | 메리 앤 터커 | 3-아릴옥시-3-치환된 프로판아민 |
NL195004C (nl) | 1987-03-04 | 2003-11-04 | Novartis Ag | Fenylcarbamaat bevattend farmaceutisch preparaat. |
GB8814057D0 (en) | 1988-06-14 | 1988-07-20 | Lundbeck & Co As H | New enantiomers & their isolation |
US5006528A (en) | 1988-10-31 | 1991-04-09 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril derivatives |
US5122522A (en) | 1989-06-21 | 1992-06-16 | The Trustees Of The University Of Pennsylvania | Treatment and control of ocular development |
CA2002182C (en) | 1989-11-03 | 2000-06-13 | Richard J. Wurtman | Compositions for treating the premenstrual or late luteal phase syndrome and methods for their use |
IE913473A1 (en) * | 1990-10-15 | 1992-04-22 | Fujisawa Pharmaceutical Co | Quinazoline derivatives and their preparation |
HU219778B (hu) | 1990-12-21 | 2001-07-30 | Gyógyszerkutató Intézet Közös Vállalat | Eljárás N-acil-2,3-benzodiazepin-származékok, savaddíciós sóik és az ezeket tartalmazó gyógyászati készítmények előállítására, valamint a vegyületek egy csoportja, és az ezeket tartalmazó gyógyászati készítmények |
ATE157656T1 (de) | 1991-10-31 | 1997-09-15 | Asta Medica Ag | Neue phthalazine, die in 1-stellung eine ether- gruppierung enthalten und verfahren zu deren herstellung |
GB9125485D0 (en) | 1991-11-29 | 1992-01-29 | Merck Sharp & Dohme | Therapeutic agents |
WO1993024442A1 (en) | 1992-05-29 | 1993-12-09 | Yamanouchi Pharmaceutical Co., Ltd. | Medicine containing benzoic acid derivative and novel benzoic acid derivative |
US5597922A (en) | 1994-07-29 | 1997-01-28 | State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University And The University Of Oregon | Glycine receptor antagonist pharmacophore |
PT101732B (pt) | 1995-06-30 | 1997-12-31 | Portela & Ca Sa | Novas di-hidrodibenzo<b,f>azepinas substituidas processo para a sua preparacao composicoes farmaceuticas que as contem e utilizacao dos novos compostos na preparacao de composicoes farmaceuticas empregues em doencas do sistema nervoso |
GB9514451D0 (en) | 1995-07-14 | 1995-09-13 | Chiroscience Ltd | Sustained-release formulation |
US5773478A (en) | 1995-07-14 | 1998-06-30 | Medeva Europe Limited | Composition comprising methylphenidate and another drug |
US5773434A (en) | 1995-08-30 | 1998-06-30 | Gary A. Rogers | Facilitation of AMPA receptor-mediated synaptic transmission in brain as a treatment for schizophrenia |
US5922736A (en) | 1995-12-04 | 1999-07-13 | Celegene Corporation | Chronic, bolus administration of D-threo methylphenidate |
US5908850A (en) | 1995-12-04 | 1999-06-01 | Celgene Corporation | Method of treating attention deficit disorders with d-threo methylphenidate |
US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
GB9604943D0 (en) | 1996-03-08 | 1996-05-08 | Chiroscience Ltd | Resolution |
JP2000511883A (ja) | 1996-04-19 | 2000-09-12 | ノボ ノルディスク アクティーゼルスカブ | ホスホチロシン認識ユニットを有する分子のモジュレーター |
AU4416197A (en) | 1996-09-17 | 1998-04-14 | Regents Of The University Of California, The | Positive ampa receptor modulation to enhance brain neurotrophic factor expression |
UA54403C2 (ru) | 1996-10-01 | 2003-03-17 | Н'Юросерч А/С | Производные индол-2,3-дион-3-оксима, фармацевтическая композиция, способ лечения расстройства или заболевания млекопитающих, в том числе человека и способ получения производных индол-2,3-дион-3-оксима |
ID21927A (id) | 1996-10-24 | 1999-08-12 | Novartis Ag | Asam aminoalkanafosfonat tersubstitusi |
DE19650975A1 (de) | 1996-12-09 | 1998-06-10 | Basf Ag | Neue heterocyclisch substituierte Benzamide und deren Anwendung |
DE69823339T2 (de) | 1997-02-28 | 2005-05-12 | Pfizer Products Inc., Groton | Atropisomere 3-heteroaryl-4(3h)-chinazolinone zur behandlung von neurodegenerativen und cns-trauma zuständen |
US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
TW403740B (en) | 1997-06-10 | 2000-09-01 | Novartis Ag | Novel crystal modifications of the compound 1-(2,6-difluorobenzyl)-1H-1,2,3-triazole-4-carboxamide |
US6375990B1 (en) | 1997-10-09 | 2002-04-23 | Emory University | Method and devices for transdermal delivery of lithium |
GB9721497D0 (en) | 1997-10-09 | 1997-12-10 | Ciba Geigy Ag | Organic compounds |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
US6100401A (en) | 1998-04-20 | 2000-08-08 | Novartris Ag | Process for preparing the d-threo isomer of methylphenidate hydrochloride |
EP1002535A1 (en) | 1998-10-28 | 2000-05-24 | Hrissanthi Ikonomidou | New use of glutamate antagonists for the treatment of cancer |
US6162919A (en) | 1998-12-03 | 2000-12-19 | Novartis Ag | Process for preparing the d-threo isomer of methylphenidate hydrochloride |
SK10572002A3 (sk) * | 2000-01-24 | 2003-10-07 | Warner-Lambert Company | 3-Aminochinazolín-2,4-diónové antibakteriálne činidlá |
US7501429B2 (en) | 2001-04-11 | 2009-03-10 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
US20050037445A1 (en) | 2001-06-25 | 2005-02-17 | Poulsen Hans Skovgaard | Oncology drug innovation |
US20030144234A1 (en) | 2001-08-30 | 2003-07-31 | Buxton Francis Paul | Methods for the treatment of chronic pain and compositions therefor |
US20060264508A1 (en) | 2001-10-16 | 2006-11-23 | Stone Richard A | Modulation of ocular growth and myopia by gaba drugs |
AU2002349705A1 (en) | 2001-12-03 | 2003-06-17 | Japan Tobacco Inc. | Azole compound and medicinal use thereof |
AU2003220825A1 (en) | 2002-03-29 | 2003-10-13 | Yamanouchi Pharmaceutical Co., Ltd. | Remedy for glioblastoma |
JP4175846B2 (ja) | 2002-08-08 | 2008-11-05 | 独立行政法人科学技術振興機構 | Ampa型グルタミン酸受容体サブユニットの発現による脳腫瘍細胞の増殖と浸潤の抑制 |
WO2004028634A1 (en) | 2002-09-25 | 2004-04-08 | The Board Of Trustees Of The University Of Illinois | Method and composition for treating alzheimer's disease and dementias of vascular origin |
GB0223730D0 (en) | 2002-10-11 | 2002-11-20 | Novartis Ag | Organic compounds |
CA2511178A1 (en) | 2002-12-20 | 2004-07-15 | Migenix Corp. | Ligands of adenine nucleotide translocase (ant) and compositions and methods related thereto |
CA2505195C (en) | 2002-12-23 | 2012-07-10 | Icagen, Inc. | Quinazolinones as potassium channel modulators |
ES2308139T3 (es) | 2003-01-29 | 2008-12-01 | Asterand Uk Limited | Antagonista de receptos ep4. |
WO2005030217A1 (en) | 2003-09-23 | 2005-04-07 | Merck & Co., Inc. | Quinazoline potassium channel inhibitors |
CA2445743A1 (en) | 2003-10-08 | 2005-04-08 | The University Of British Columbia | Methods for modulating neuronal responses |
GB0416730D0 (en) * | 2004-07-27 | 2004-09-01 | Novartis Ag | Organic compounds |
GB0507298D0 (en) | 2005-04-11 | 2005-05-18 | Novartis Ag | Organic compounds |
-
2005
- 2005-04-11 GB GBGB0507298.8A patent/GB0507298D0/en not_active Ceased
-
2006
- 2006-04-06 MY MYPI20094250A patent/MY149070A/en unknown
- 2006-04-06 MY MYPI20061558A patent/MY142474A/en unknown
- 2006-04-07 PE PE2006000379A patent/PE20061306A1/es not_active Application Discontinuation
- 2006-04-07 AR ARP060101392A patent/AR053047A1/es unknown
- 2006-04-07 PE PE2009000810A patent/PE20091366A1/es not_active Application Discontinuation
- 2006-04-07 GT GT200600144AK patent/GT200600144AA/es unknown
- 2006-04-07 GT GT200600144A patent/GT200600144A/es unknown
- 2006-04-09 SA SA06270089A patent/SA06270089B1/ar unknown
- 2006-04-09 SA SA109300363A patent/SA109300363B1/ar unknown
- 2006-04-10 AU AU2006233639A patent/AU2006233639B2/en not_active Ceased
- 2006-04-10 KR KR1020097022601A patent/KR101162827B1/ko not_active IP Right Cessation
- 2006-04-10 PL PL06724185T patent/PL1871749T3/pl unknown
- 2006-04-10 TW TW095112596A patent/TWI385158B/zh not_active IP Right Cessation
- 2006-04-10 RU RU2007141566/04A patent/RU2435760C2/ru not_active IP Right Cessation
- 2006-04-10 ES ES12158895.8T patent/ES2524316T3/es active Active
- 2006-04-10 EP EP12158903A patent/EP2476671A1/en not_active Withdrawn
- 2006-04-10 BR BRPI0608617-9A patent/BRPI0608617A2/pt not_active IP Right Cessation
- 2006-04-10 PL PL12158895T patent/PL2468732T3/pl unknown
- 2006-04-10 DK DK12158895.8T patent/DK2468732T3/da active
- 2006-04-10 SG SG2011089851A patent/SG177182A1/en unknown
- 2006-04-10 EP EP06724185A patent/EP1871749B1/en active Active
- 2006-04-10 RU RU2011131276/04A patent/RU2509764C2/ru not_active IP Right Cessation
- 2006-04-10 EP EP12158899A patent/EP2463278A1/en not_active Withdrawn
- 2006-04-10 KR KR1020077023171A patent/KR100990783B1/ko not_active IP Right Cessation
- 2006-04-10 EP EP12158895.8A patent/EP2468732B1/en active Active
- 2006-04-10 NZ NZ590463A patent/NZ590463A/en not_active IP Right Cessation
- 2006-04-10 TW TW101133845A patent/TWI440461B/zh not_active IP Right Cessation
- 2006-04-10 CN CN2012102580549A patent/CN102807531A/zh active Pending
- 2006-04-10 SI SI200631844T patent/SI2468732T1/sl unknown
- 2006-04-10 SI SI200631459T patent/SI1871749T1/sl unknown
- 2006-04-10 DK DK06724185.1T patent/DK1871749T3/da active
- 2006-04-10 WO PCT/EP2006/003251 patent/WO2006108591A1/en active Application Filing
- 2006-04-10 ES ES06724185T patent/ES2392542T3/es active Active
- 2006-04-10 PT PT121588958T patent/PT2468732E/pt unknown
- 2006-04-10 NZ NZ560964A patent/NZ560964A/en not_active IP Right Cessation
- 2006-04-10 IN IN785DEN2012 patent/IN2012DN00785A/en unknown
- 2006-04-10 JO JO200693A patent/JO2770B1/en active
- 2006-04-10 ZA ZA200807421A patent/ZA200807421B/en unknown
- 2006-04-10 MX MX2007012592A patent/MX2007012592A/es active IP Right Grant
- 2006-04-10 PT PT06724185T patent/PT1871749E/pt unknown
- 2006-04-10 JP JP2008505790A patent/JP4898783B2/ja not_active Expired - Fee Related
- 2006-04-10 CA CA 2601986 patent/CA2601986C/en not_active Expired - Fee Related
- 2006-04-10 CN CN2006800116660A patent/CN101155789B/zh not_active Expired - Fee Related
- 2006-04-10 US US11/911,040 patent/US7655666B2/en not_active Expired - Fee Related
-
2007
- 2007-08-23 ZA ZA200707111A patent/ZA200707111B/xx unknown
- 2007-08-27 IL IL185544A patent/IL185544A/en not_active IP Right Cessation
- 2007-10-10 TN TNP2007000383A patent/TNSN07383A1/en unknown
- 2007-10-29 MA MA30330A patent/MA29411B1/fr unknown
- 2007-11-09 NO NO20075749A patent/NO20075749L/no not_active Application Discontinuation
-
2008
- 2008-04-02 HK HK08103724.9A patent/HK1113790A1/xx not_active IP Right Cessation
-
2009
- 2009-09-29 US US12/569,402 patent/US8012988B2/en not_active Expired - Fee Related
-
2011
- 2011-02-28 AU AU2011200888A patent/AU2011200888B2/en not_active Ceased
- 2011-07-28 US US13/192,816 patent/US8513268B2/en not_active Expired - Fee Related
- 2011-09-26 JP JP2011209578A patent/JP5525500B2/ja not_active Expired - Fee Related
-
2012
- 2012-04-19 EC ECSP12007795 patent/ECSP12007795A/es unknown
- 2012-06-28 IL IL220682A patent/IL220682A/en not_active IP Right Cessation
- 2012-10-26 HR HRP20120867TT patent/HRP20120867T1/hr unknown
- 2012-10-31 CY CY20121101042T patent/CY1113573T1/el unknown
-
2013
- 2013-07-01 US US13/932,173 patent/US20130296332A1/en not_active Abandoned
-
2014
- 2014-11-18 HR HRP20141116TT patent/HRP20141116T1/hr unknown
- 2014-11-19 CY CY20141100963T patent/CY1115767T1/el unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995019346A1 (en) * | 1994-01-14 | 1995-07-20 | Sandoz Ltd. | Quinazoline-2,4-diones |
RU2214405C2 (ru) * | 1998-02-18 | 2003-10-20 | НьюроСёрч А/С | Новые соединения и их применение в качестве положительных модуляторов амра-рецепторов |
US6562839B1 (en) * | 1999-02-26 | 2003-05-13 | Kyorin Pharmaceutical Co., Ltd. | 6-substituted heteroquinolinecarboxylic acid derivatives and addition salts thereof and processes for the preparation of both |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2509764C2 (ru) | 1н-хиназолин-2,4-дионы | |
RU2498988C2 (ru) | Ингибиторы активности протеинтирозинкиназы | |
RU2401658C2 (ru) | Гетероциклические ингибиторы аспартилпротеазы | |
BRPI0418099A (pt) | compostos, composição farmacêutica, e uso de um composto | |
MA38380A1 (fr) | Inhibiteurs quinazoline de l'activation des formes mutantes du récepteur de croissance épidermique (egfr) | |
BR0312573A (pt) | Derivados de fenil-[4-(3-fenil-1h-pirazol-4-il)-pirimidin-2-il]-amina | |
CL2007003827A1 (es) | Compuestos derivados de n-(2-aza-biciclo(3.1.0)hex-3-ilmetil)amida; y su uso para prevenir o tratar la depresion, neurosis, esquizofrenia, ansiedad, adicciones, epilepsia, dolor, enfermedades cardiacas, entre otras. | |
EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
BRPI0307355B8 (pt) | composto de 2,4-pirimidinodiamina, e, composição farmacêutica compreendendo o mesmo | |
EA200700362A1 (ru) | Конъюгат, содержащий антивирусное соединение, в частности ингибирующее вич, фармацевтическая композиция и набор стандартной дозы лекарственного препарата на его основе, способ ингибирования с его помощью | |
WO2005032471A3 (en) | Benzylether and benzylamino beta-secretase inhibitors for the treatment of alzheimer's disease | |
ATE527243T1 (de) | Calciumkanal-antagonisten vom typ chinazolinon t | |
EA201690265A3 (ru) | Фармацевтические композиции, содержащие замещенные ациланилиды | |
WO2005072308A3 (en) | Cgrp receptor antagonists | |
TW200621249A (en) | Substituted amide beta secretase inhibitors | |
JP2004534850A5 (ru) | ||
EA200802007A1 (ru) | Соединения, потенцирующие рецептор амра, и применение указанных соединений в медицине | |
BRPI0412893A (pt) | composto, composição farmacêutica, uso de um composto, e, métodos de prevenção, tratamento ou melhora de doenças ou condições inflamatórias, ou doenças ou condições oftálmicas, de tratamento ou melhora de cáncer e para a produção de um composto | |
CY1110316T1 (el) | Χρηση πιπαμπερονης και ενος sndri, snri ή ssri για την θεραπεια διαταραχων ψυχικης διαθεσης ή αγχους | |
RS51069B (sr) | Upotreba oksikodona za tretiranje visceralnog bola | |
CL2004001365A1 (es) | Compuestos derivados de 3-fluoropiperidina; composicion farmaceutica que lo comprende; y uso del compuesto para tratar o prevenir el dolor o la enfermedad de parkinson. | |
CL2003002293A1 (es) | Compuestos derivados de indazol; su composicion farmaceutica; su uso en el tratamiento de hipertension ocular. | |
EA200900269A1 (ru) | Лекарственные комбинации для лечения заболеваний дыхательных путей | |
EA201992817A1 (ru) | Синергетические композиции, содержащие (r)-димирацетам (1) и (s)-димирацетам (2) в нерацемическом соотношении | |
WO2006005142A3 (en) | Mono- and polycyclic compounds with therapeutic activity, pharmaceutical compositions including them and intermediates for making them |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20150411 |